

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Fayette Memorial Hospital d/b/a Fayette Regional Health System</p> <p>2. 1941 Virginia Avenue Connersville, Indiana 47331</p>	<p>In accordance with letters dated July 23, 2013, and August 9, 2013,</p> <p>3. License No. 13-16518-01 is amended in its entirety to read as follows:</p> <p>4. Expiration Date: January 31, 2021</p> <p>5. Docket No. 030-11441 Reference No.</p>
---	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. One curie
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 5 millicuries

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. In vitro studies.

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities located at 1941 Virginia Avenue, Connersville, Indiana.
- 11. The Radiation Safety Officer (RSO) for this license is Patrick Byrne, DABR, CHP, DABSNM.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.
13-16518-01Docket or Reference No.
030-11441**Amendment No. 17**

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized UserMaterial and Use

Peter D. Arfken, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

Edward R. Bartley, M.D.

10 CFR 35.100, 35.200, and 31.11.

Eric E. Beltz, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

Homer F. Beltz, M.D.

10 CFR 35.100, 35.200, and 31.11.

Jack M. Drew, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

Janalyn P. Ferguson, M.D.

10 CFR 35.100, 35.200, and 31.11.

Eric D. Elliott, M.D.

10 CFR 35.100, 35.200, and 31.11.

Steven A. Fritsch, M.D.

10 CFR 35.100, 35.200, and 31.11.

Charles C. Mulry, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

Jane S. Mitchell, M.D.

10 CFR 35.100, 35.200, and 31.11.

Jack J. Moss, M.D.

10 CFR 35.100, 35.200, and 31.11.

John A. Morton, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

Jeffrey I. Reider, M.D.

10 CFR 35.100, 35.200, and 31.11.

Mitchell A. Russ, M.D.

10 CFR 35.100, 35.200, and 31.11.

Lori J. Wells, M.D.

10 CFR 35.100, 35.200, and 31.11.

Brian J. Wiegel, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

David R. Gulliver, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

Michael S. Skulski, M.D.

10 CFR 35.100, 35.200, and 31.11.

Thomas Hagman, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

Margaret Brengle, M.D.

10 CFR 35.100, 35.200, and 31.11.

Charles A. Lerner, M.D.

10 CFR 35.100, 35.200, and 31.11.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.
13-16518-01Docket or Reference No.
030-11441**Amendment No. 17**Authorized User

J. Michael Phelps, Jr., M.D.

Timothy L. Davis, M.D.

Vincent P. Mathews, M.D.

John Mark Michael, M.D.

Theodore P. Labus, M.D.

Cristina N. Shinaver, M.D.

Frank J. Pistoia, M.D.

Richard L. Hallet, M.D.

Caryn Cockerill Anderson, M.D.

Warren Kent Hansen, M.D.

Carlo Roberto Lazzaro, M.D.

Laura Dugan, M.D.

Jonathan Kahn, M.D.

Patricia Ellen Ladd, M.D.

Michael S. Conley, M.D.

Marc P. Underhill, M.D.

Vincent L. Flanders, M.D.

Sara Shull, M.D.

Ryan N. Sauer, M.D.

Material and Use

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

10 CFR 35.100, 35.200, and 31.11.

10 CFR 35.100, 35.200, 35.300, and 31.11.

10 CFR 35.100, 35.200, 35.300, and 31.11.

10 CFR 35.100, 35.200, 35.300, and 31.11.

10 CFR 35.100, 35.200, and 31.11.

10 CFR 35.100, 35.200, 35.300, and 31.11.

10 CFR 35.100, 35.200, and 31.11.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

10 CFR 35.100, 35.200, and 31.11.

10 CFR 35.100, 35.200, 35.300, and 31.11.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

10 CFR 35.100, 35.200, and 31.11.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries) and 31.11.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131), and 31.11.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.
13-16518-01Docket or Reference No.
030-11441**Amendment No. 17**Authorized User

Larry L. Stover, M.D.

Kelly K. Horst, M.D.

John Marvel, M.D.**James Currier, M.D.**Material and Use

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131), and 31.11.

10 CFR 35.100, 35.200, 35.300 (limited to sodium iodide I-131), and 31.11.

10 CFR 35.300.**10 CFR 35.300.**


13. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated October 12, 2010.

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date SEP 19 2013

By


Toye L. Simmons
Materials Licensing Branch
Region III